ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.85
-0.14%
US Tech 100
19,181.60
-0.43%
S&P 500
5,460.48
-0.41%
US Dollar vs CAD
1.36945
0.00%
Bitcoin
60,967.86
1.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. CSE
  6. Revive Therapeutics Ltd (RVV)

  7. Revive Therapeutics Ltd (RVV) News

RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:CSE:RVV
DateTimeSourceHeadlineSymbolCompany
04/18/20229:26AMInvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
04/12/20227:00AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
03/29/20228:57AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
02/14/20225:53AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
01/17/20228:13AMInvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsCSE:RVVRevive Therapeutics Ltd
01/07/20227:05AMInvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
08/18/20215:00AMInvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerCSE:RVVRevive Therapeutics Ltd
08/12/20218:56AMInvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationCSE:RVVRevive Therapeutics Ltd
08/10/20217:52AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineCSE:RVVRevive Therapeutics Ltd
06/28/20217:00AMInvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketCSE:RVVRevive Therapeutics Ltd
06/08/20218:12AMInvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaCSE:RVVRevive Therapeutics Ltd
05/17/20218:48AMInvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripCSE:RVVRevive Therapeutics Ltd
05/03/20218:32AMInvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19CSE:RVVRevive Therapeutics Ltd
04/22/20217:26AMInvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contCSE:RVVRevive Therapeutics Ltd
03/24/20218:15AMInvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
02/11/20217:05AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramCSE:RVVRevive Therapeutics Ltd
01/27/20217:13AMInvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentCSE:RVVRevive Therapeutics Ltd
01/18/20218:51AMInvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesCSE:RVVRevive Therapeutics Ltd
12/31/20207:30AMInvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyCSE:RVVRevive Therapeutics Ltd
12/22/202010:05AMInvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramCSE:RVVRevive Therapeutics Ltd
10/30/202012:39PMInvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
07/31/20208:46AMInvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
04/23/20208:47AMInvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical TrialCSE:RVVRevive Therapeutics Ltd
 Showing the most relevant articles for your search:CSE:RVV

Your Recent History

TG
A3LEFW
Crdit Mutuel Home Loan
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved